MODIFIED PTO/SB/08a (05-07) Approved for use through 11/30/2007.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/588,485
Confirmation Number	8206
Filing Date	August 4, 2006
First Named Inventor	Masaaki HIRANO
Art Unit	1626
Examiner Name	Valerie Rodriguez-Garcia
Attorney Docket Number	Q96434

U.S. PATENTS							
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1						

	U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initials*	L Cite No. 1. Publication Number		Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Lines, WI Relevant Passages or Relevant Passages		
	1	2005/0267110	A1	2005-12-01	M. Hirano		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	1	2000-95767	JP		2000-04-04	Y. Imaeda et al.		Abstract
	2	1 300 398	EP	A1	2003-04-09	Masaaki Hirano et al.		
	3	2005/118556	wo	A1	2005-12-15	Masaaki Hirano et al.		Abstract
	4	1 752 452	EP	A1	2007-02-14	Masaaki Hirano et al.		
	5	02/102401	wo	A1	2002-12-27	Jorgen Engel et al.		
	6	2005/030736	wo	A1	2005-04-07	Giovanni Meazza et al.		
	7	01-249792	JP	Α	1989-10-05	K. Kato et al.		Abstract

		NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
	1	CHARLES HUGGINS ET AL., "Studies on Prostatic Cancer", Cancer Research, 1, 293-297 (1941).				
	2	L. BOKSER ET AL., "Prolonged Inhibition of Luteinizing Hormone and Testosterone Levels in Male Rats with the Luteinizing Hormone-Releasing Hormone Antagonist SB-75", Proc. Natl. Acad. Sci. USA, 87, pp. 7100-7104, Sept. 1990.				
	3	ANA MARIA COMARU-SCHALLY ET AL., "Efficacy and Safety of Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix in the Treatment of Symptomatic Benign Prostatis Hyperplasia," Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 11, pp. 3826-3831 (1998).				
	4	I.B. DZVINCHUK ET AL., "Formation of Unsymmetrical 2-(Diacylmethylene)-2,3-Dihydro-1 H-Benzimidazoles During Acidolysis of 1-Benzoyl-2-((3-Benzoyloxy-(3-Phenylvinyl)-1 H-Benzimidazole), Chemistry of Heterocyclic Compounds, 37(5), 554-559 (2001).				
	5	SEMA OZTURK ET AL., "Crystal Structure of 2-Dibenzoylmethyl Benzimidazole", Analytical Sciences, Vol. 17,pp. 1133-1134, (2001).				
	6	MANFRED AUGUSTIN ET AL, "Synthesis and reactions of 2,2-diacylketene heteroacetals", Zeitschrift fuer Chemie(1980), 20(3), 96-7.				
	7	JUNKO ISHIDA et al., "Antitumor Agents. Part 214 : Synthesis and Evaluation of Curcumin Analogues as Cytotoxic Agents," Bioorganic & Medicinal Chemistry 10 (2002) 3481-3487.				
	8	Science of Synthesis, "Product Subclass 17: 1,1-Bis(nitrogen - functionalized) Alk - 1-enes", 24, 571-705 (2005).				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

EXAMINER SIGNATURE					
Examiner Signature		Date Considered			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.